MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, Son J, Yu JW. · 2019
Read MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. by Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, Son J, Yu JW. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6329843.txt.
Introduction
Lee and co-authors pin a brain immune sensor to neuron loss in a Parkinson's model. Their study appeared in Cell Death and Differentiation. Parkinson's disease kills dopamine neurons in a midbrain region. Brain inflammation likely helps drive that loss. The team used MPTP, a toxin that mimics the disease in mice. They focused on the NLRP3 inflammasome in microglia.
Mice lacking NLRP3 fared far better after the toxin. They kept more dopamine neurons and moved more normally. The toxin also failed to summon microglia without NLRP3. Key inflammatory signals, IL-1 beta and caspase-1, stayed off. In cell cultures, mitochondrial reactive oxygen drove the sensor. Blocking this pathway may slow Parkinson's damage, the authors suggest.
Catalog record
| CREATOR | Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, Son J, Yu JW. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration By Eunju Lee, Inhwa Hwang, Sangjun Park, Sujeong Hong, Boreum Hwang, Yoeseph Cho, Junghyun Son, Je-Wook Yu Published in: Cell Death and Differentiation DOI: 10.1038/s41418-018-0124-5 ABSTRACT Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and the reduction of dopamine levels in the striatum. Although details of the molecular mechanisms underlying dopaminergic neuronal death in PD remain unclear, neuroinflammation is also considered a potent mediator in the pathogenesis and progression of PD. In the present study, we present evidences that microglial NLRP3 inflammasome activation is critical for dopaminergic neuronal loss and the subsequent motor deficits in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Specifically, NLRP3 deficiency significantly reduces motor dysfunctions and dopaminergic neurodegeneration of MPTP-treated mice. Furthermore, NLRP3 deficiency abolishes MPTP-induced microglial recruitment, interleukin-1β production and caspase-1 activation in the SN of mouse brain. In primary microglia and mixed glial cell cultures, MPTP/ATP treatment promotes the robust assembly and activation of the NLRP3 inflammasome via producing mitochondrial reactive oxygen species. Consistently, 1-methyl-4-phenyl-pyridinium (MPP+) induces NLRP3 inflammasome activation in the presence of ATP or nigericin treatment in mouse bone-marrow-derived macrophages. These findings reveal a novel priming role of neurotoxin MPTP or MPP+ for NLRP3 activation. Subsequently, NLRP3 inflammasome-active microglia induces profound neuronal death in a microglia-neuron co-culture model. Furthermore, Cx3Cr1CreER-based microglia-specific expression of an active NLRP3 mutant greatly exacerbates motor deficits and dopaminergic neuronal loss of MPTP-treated mice. Taken together, our results indicate that microglial NLRP3 inflammasome activation plays a pivotal role in the MPTP-induced neurodegeneration in PD. INTRODUCTION Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and a subsequent reduction in the striatal concentration of dopamine, which leads to motor impairment [1, 2]. Although the precise etiology of PD remains unclear, the aggregation of α-synuclein in dead or dying dopaminergic neurons has been reported [3, 4] and is considered a primary cause of dopaminergic neuron degeneration. However, the molecular mechanisms underlying the formation and neurotoxicity of α-synuclein aggregates have not yet been elucidated [5]. In addition to the potential role of α-synuclein in PD pathogenesis, neuroinflammation has also been implicated in the loss of dopaminergic neurons [6, 7]. To this end, increased pro-inflammatory cytokine levels have been found in striatal dopaminergic regions or cerebrospinal fluid of PD patients [8, 9], and in the SN in an animal model of PD [10]. Additionally, activated microglia might contribute to neuronal damage via the release of pro-inflammatory cytokines and neurotoxic products [11]. Further, histological data revealed an increased number of activated microglia in the SN of PD patients, concurrent with the degeneration of dopaminergic neurons [12, 13]. Hence, the regulation of neuroinflammation mediated by microglia might provide a potential therapeutic strategy to mitigate the progression of PD. Inflammasome is a caspase-1-activating multi-protein complex comprised of sensor molecules such as NOD-like receptor family, pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1 [14]. In microglia, NLRP3 inflammasome can be assembled upon stimulation with accumulated endogenous metabolites such as fibrillar amyloid β and 25-hydroxycholesterol [15, 16]. The assembly of an inflammasome promptly results in the activation of caspase-1 and the subsequent secretion of interleukin (IL)-1β, which might play a major role in the initiation of pro-inflammatory responses around microglia. Recent studies demonstrated a significant contribution of NLRP3 inflammasome to the progression of Alzheimer's disease (AD), the most common neurodegenerative disease [15, 17]. Amyloid β, a risk factor for AD pathogenesis, could promote the activation of the NLRP3 inflammasome pathway in microglia [15], and NLRP3 deficiency clearly attenuates AD phenotypes, including the loss of spatial memory, in aged APP/PS1 mice [17]. Of particular interest, fibrillar α-synuclein was shown to induce the secretion of IL-1β from peripheral blood mononuclear cells and microglia [18, 19]. Furthermore, a recent study revealed that caspase-1 deficiency significantly reduces dopaminergic neuronal death of mice following intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound commonly used in animal models to induce PD [20]. Interestingly, Wang et al. showed that caspase-1 could process α-synuclein into a truncated, aggregation-prone form that facilitates its aggregation [21]. Furthermore, blocking the IL-1 receptor by IL-1Ra in an animal study significantly attenuated the degeneration of dopaminergic neurons [22, 23]. These recent studies suggest that caspase-1 and the inflammasome pathway are potentially associated with PD pathogenesis or progression. Nonetheless, the mechanisms underlying the contribution of inflammasome signaling to dopaminergic neuron death remain largely unknown. In the present study, we provide evidences that neurotoxin MPTP activates the NLRP3 inflammasome in microglia, and that the NLRP3 inflammasome-activated microglia plays a pivotal role in the neurodegeneration associated with PD. RESULTS NLRP3 deficiency alleviates motor dysfunctions and dopaminergic neuronal loss in MPTP-treated mice To induce PD-like symptoms in mice, we administered intraperitoneal injections of MPTP to mice as previously described [24]. The administration of MPTP caused a significant impairment of motor activity as determined by a string test (Fig. 1a). Likewise, MPTP-treated mice exhibited a marked increase in the cataleptic response (Fig. 1b). The MPTP-induced motor dysfunctions were significantly attenuated in Nlrp3-deficient mice compared with Nlrp3-expressing wild type (WT) mice (Fig. 1a,b). Moreover, the MPTP-induced hindlimb clasping behavior in WT mice was markedly reduced in Nlrp3-knockout mice (Fig. 1c and Supplementary Fig. 1a). In accord with these observations, MPTP intoxication caused a severe truncal dystonia in WT mice, but the observed effects were reduced in Nlrp3-deficient mice (Supplementary Fig. 1b).Fig. 1NLRP3 deficiency attenuates motor dysfunctions and dopaminergic neuronal loss in MPTP-treated mice. a–c Nlrp3+/+ or Nlrp3−/− mice were administered with PBS or MPTP (40 mg/kg) for 5 days and then examined for motor activity impairment as described in the Methods. a The latent time to hold the bar in the string test 24 h post the final PBS or MPTP administration (Nlrp3+/+ mice, PBS (n = 6), MPTP (n = 10); Nlrp3−/− mice, PBS (n = 6), MPTP (n = 11)). b The latent time to hold the bar in the catalepsy test 1 h post the final PBS or MPTP administration. (PBS (n = 6), MPTP (n = 11)). c The severity of hindlimb clasping in PBS- (n = 6) or MPTP-treated (n = 11) mice 1 h post the final PBS or MPTP administration. d Representative immunofluorescence image of the fixed brain sections containing SN of PBS- or MPTP-treated Nlrp3+/+ or Nlrp3−/− mice after staining with anti-TH antibody (green). DAPI represents the nuclear signal (blue). Scale bars, 200 μm. e Quantification of relative TH-positive cells per DAPI in confocal images of PBS- or MPTP-treated Nlrp3 +/+ or Nlrp3−/− mice (n = 4). f Quantification of striatal dopamine levels of PBS- or MPTP-treated Nlrp3+/+ or Nlrp3−/− mice as determined by HPLC-MS/MS (Nlrp3+/+ mice, PBS (n = 11), MPTP (n = 11); Nlrp3−/− mice, PBS (n = 11), MPTP (n = 10)). Data were expressed as the mean ± SEM. Asterisks indicate significant differences (*P < 0.05, **P < 0.01, ***P < 0.001) Next, we observed dopaminergic neurons stained with an anti-tyrosine hydroxylase (TH) antibody, in the SN of the mouse brain following MPTP administration. As expected, MPTP administration caused a